Related Content
October 21, 2008 - MIV Therapeutics Inc., a developer of coatings and drug-delivery systems for cardiovascular stents ...
October 20, 2008
September 19, 2008 – Last month, MIV announced continued positive results for VESTAsync, a polymer-free drug-eluting ...
September 18, 2008July 17, 2008 - MIV Therapeutics Inc. today said its Protea ultra-thin cobalt-alloy bare metal stent has excelled in ...
July 15, 2008May 22, 2008 - MIV Therapeutics Inc. has enrolled the first patients in the registration trial of its VESTAsync polymer ...
May 21, 2008April 8, 2008 - The first-in-man study funded by MIV Therapeutics Inc. (MIV) showed that MIV's VESTAsync stents ...
April 07, 2008November 21, 2007 - MIV Therapeutics Inc. will sell all of its shares of SagaX Inc. for $4.0 million plus future ...
November 20, 2007November 14, 2007 - MIV Therapeutics Inc. announces that the Drugs Controller General of India (DCGI), the governmental ...
November 13, 2007October 16, 2007 - MIV Therapeutics Inc., a developer of coatings and drug delivery systems for cardiovascular stents ...
October 15, 2007April 9, 2007 — MIV Therapeutics Inc. has announced that its recent bench test confirmed that merging Biosync Scientific ...
April 07, 2007Two novel polymer-free drug-eluting stent coating technologies tested in a comparative animal study has concluded with ...
December 03, 2006© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now